Panacea Biotec Share News - Latest Updates, Live News & More

Latest news about Panacea Biotec

Panacea Biotec Secures ₹20.79 Crore Government Contract for Diphtheria and Tetanus Vaccine Supply 1 day ago Yesterday

Panacea Biotec Limited has received a significant government contract worth ₹20.79 crore from the Central Medical Services Society for supplying Diphtheria and Tetanus Vaccine. The contract spans from September 2026 to December 2028, representing a substantial business opportunity that validates the company's manufacturing capabilities and strengthens its position in the domestic vaccine market.

Panacea Biotec Receives Industrial Tribunal Awards on Workmen Transfer and Reinstatement 3 days ago

Panacea Biotec Receives Rectified Assessment Order, Tax Liability Reduced to Nil for AY 2015-16 6 days ago

Panacea Biotec Submits Q4 FY26 SEBI Compliance Certificate for Depositories Regulations 7 days ago

Panacea Biotec Reports Share Dematerialization Status for March 2026 7 days ago

More news about Panacea Biotec

07Apr 26

Panacea Biotec Receives Rectified Assessment Order, Tax Liability Reduced to Nil for AY 2016-17

Panacea Biotec Limited has received a rectified assessment order from the Deputy Commissioner of Income Tax, New Delhi, dated April 06, 2026, which has reduced the company's tax liability for Assessment Year 2016-17 to nil. The original assessment order dated March 01, 2026, had imposed a demand of ₹10.23 crore due to disallowed expenditures. Following the company's rectification application, errors including double addition of disallowances and omission of set-off for brought-forward losses were corrected, resulting in a positive financial impact with no adverse effects expected on the company's operations.

01Apr 26

Panacea Biotec Announces Completion of Independent Director Mukul Gupta's Tenure

Panacea Biotec Limited has formally announced the completion of Mr. Mukul Gupta's tenure as Independent Director, concluding his second and final five-year term on March 31, 2026. The pharmaceutical company filed the required regulatory intimation with NSE and BSE under SEBI LODR Regulations, with the Board expressing appreciation for his extensive contribution and guidance towards the company's business growth during his directorship.

01Apr 26

Panacea Biotec Receives ₹22.88 Crore GST Demand Order from Tax Authorities

Panacea Biotec Limited received a GST demand order of ₹22.88 crore from CGST authorities on March 30, 2026, comprising ₹11.44 crore for alleged non-payment of GST and equal penalty amount. The demand relates to a corporate guarantee of ₹864 crore provided from April 2019 to March 2022. The company has secured interim stay protection from Punjab & Haryana High Court and maintains the demand is not maintainable, expecting no significant financial impact on operations.

30Mar 26

Panacea Biotec Independent Director CA Rajesh Jain Resigns Due to Professional Commitments

Panacea Biotec Limited announced CA Rajesh Jain's resignation as Non-Executive Independent Director effective June 30, 2026, citing professional commitments and increasing regulatory demands. The resignation applies to both the company and its subsidiary Panacea Biotec Pharma Limited. He will also step down from all Board Committee positions. The company expressed appreciation for his contributions during his tenure.

28Mar 26

Panacea Biotec's Tax Appeals Dismissed, Faces ₹9.38 Crore Penalty Demand

Panacea Biotec Limited faced a setback as CIT(A) dismissed its appeals against ₹9.38 crore penalty orders for alleged income under-reporting across assessment years 2017-18, 2020-21, and 2021-22. The company maintains the demand is not maintainable and plans to appeal to higher authorities. Despite the substantial penalty amount, Panacea Biotec expects no material impact on its financial or operational activities.

11Mar 26

Panacea Biotec Subsidiary Receives Tax Relief as Demand Reduced from ₹1.58 Crore to ₹0.81 Crore

Panacea Biotec Limited announced that its subsidiary PBPL received a favorable tax order from Maharashtra authorities, reducing the demand from ₹1.58 crore to ₹0.81 crore. The original demand was related to alleged excess Input Tax Credit and other tax liabilities from FY 2024-25. Despite the reduction, the company considers the revised demand not maintainable and plans to file an appeal with the appellate authority. The company expects no material impact on its operations or financial position from this matter.

11Mar 26

Panacea Biotec Wins Major Tax Appeal as ITAT Deletes ₹329.49 Crore Demand

Panacea Biotec has achieved a significant legal victory with the Income Tax Appellate Tribunal (ITAT) New Delhi ruling in its favor, resulting in the deletion of a ₹329.49 Crore tax demand spanning Assessment Years 2005-06 to 2012-13. The tribunal dismissed all DCIT appeals and allowed the Company's appeals, with the order specifically confirming the deletion of all expense disallowances and nullifying substantial contingent tax liabilities that had persisted for over a decade.

06Mar 26

Panacea Biotec Receives ₹10.23 Crore Income Tax Demand Order for Assessment Year 2016-17

Panacea Biotec Limited received an income tax demand order of ₹10.23 crore for Assessment Year 2016-17 from the Deputy Commissioner of Income Tax, Delhi. The demand resulted from disallowances of certain expenditures under Section 37 of the Income Tax Act, allegedly due to incorrect categorization of expenses violating Medical Council of India regulations. The company considers the demand non-maintainable, citing revised tax filings showing no taxable income due to brought-forward losses, and plans to file rectification applications and appeals while expecting no significant impact on its operations.

02Mar 26

Panacea Biotec Receives Income Tax Demand Order of ₹45.71 Crore for Assessment Year 2015-16

Panacea Biotec Limited received an income tax demand order of ₹45.71 crore for Assessment Year 2015-16 from Delhi's Deputy Commissioner of Income Tax office on March 01, 2026. The demand arises from disallowed deductions under Section 37 due to incorrect expense categorisation allegedly violating Medical Council of India regulations. The company considers the demand non-maintainable citing revised tax filings showing no tax liability due to brought-forward losses, and plans legal recourse including rectification application and appeal, expecting no significant operational impact.

12Feb 26

Panacea Biotec Reports Q3 FY26 Financial Results with Mixed Standalone and Consolidated Performance

Panacea Biotec Limited reported Q3 FY26 unaudited financial results showing contrasting performance between standalone and consolidated operations. Standalone business recorded revenue of ₹9,931 lakh with net loss of ₹736 lakh, while consolidated operations achieved revenue of ₹16,519 lakh with net profit of ₹389 lakh. The results were approved by the Board on February 11, 2026, and published in compliance with SEBI regulations.

05Feb 26

Panacea Biotec Discloses GMP Certificate Revocation Following NCPHP Inspection at Baddi

Panacea Biotec Limited disclosed regulatory challenges following NCPHP's inspection of its Baddi facility from January 26-31, 2026, resulting in GMP certificate revocation due to non-compliance with EU Directive 2017/1572. The company faces restricted supplies of non-vital products except for ongoing oncology treatments, though it clarified no oncology products are supplied to EU markets. With EU revenue representing only 0.32% of total consolidated revenues, the financial impact appears limited, while the company implements corrective measures and plans re-inspection to restore certifications.

08Jan 26

Panacea Biotec Shares Jump 7% After Completing DengiAll Dengue Vaccine Phase III Enrollment

Panacea Biotec completed enrollment of 10,335 participants in Phase III clinical trial for DengiAll, its tetravalent dengue vaccine candidate, leading to 7% stock gain. The company has been developing this indigenous single-shot dengue vaccine since 2008, targeting 2027 market entry. DengiAll uses live, weakened strains of all four dengue virus serotypes and will now enter a two-year monitoring phase to assess efficacy and immunogenicity.

26Dec 25

Panacea Biotec Receives Income Tax Demand Orders Worth ₹9.38 Crores for Alleged Under-Reporting

Panacea Biotec received income tax demand orders totaling ₹9.38 crores on December 26, 2025, for alleged under-reporting of income across assessment years 2017-18, 2020-21, and 2021-22. The demands were issued under Section 156 of the Income Tax Act by the Assistant Commissioner of Income Tax, Central Circle 29, Delhi. The company considers the demands not maintainable and plans to file appeals, expecting no significant impact on its operations or financial activities.

26Dec 25

Panacea Biotec Enhances UNICEF Vaccine Supply Contract; Taro Pharma Recalls Antifungal Medication

Panacea Biotec announced a significant enhancement to its UNICEF vaccine supply contract, including value increases to existing awards and a new award, marking a major development for its international operations. Separately, Taro Pharmaceutical Industries recalled over 17,000 units of Ciclopirox Shampoo in the US due to failed impurity specifications. Strides Pharma Science's US subsidiary received a Form 483 with four procedural observations following a routine FDA inspection at its New York facility.

26Dec 25

Panacea Biotec Secures Enhanced UNICEF Contract Worth Additional $8.93 Million

Panacea Biotec has secured a significant contract enhancement from UNICEF worth $8.93 million across 2026-2027 for vaccine supply. The amendment includes value increases to existing awards and an additional new award for WHO pre-qualified Pentavalent vaccine supply, reinforcing UNICEF's confidence in the company's manufacturing capabilities.

24Dec 25

Panacea Biotec Secures $8.9 Million Additional Vaccine Orders from UNICEF

Panacea Biotec has received significant updates to its UNICEF contract for supplying pentavalent vaccine Easyfive-TT, as well as new awards for pentavalent and polio vaccines. The contract updates include increased order volumes for 2026 and 2027, totaling $8.93 million (₹80.00 crores). Additionally, the company secured a long-term agreement to supply bivalent oral polio vaccine (bOPV) from April 2026 to March 2030. These developments strengthen Panacea Biotec's position as a key supplier of WHO pre-qualified vaccines for global immunization programs.

15Dec 25

Panacea Biotec Appoints Vinod Goel as CFO and Ankit Jain as Company Secretary

Panacea Biotec Limited has appointed Vinod Goel as Chief Financial Officer and Ankit Jain as Company Secretary, effective December 16, 2025. The appointments follow Devender Gupta's resignation from the CFO position and were approved by the Board of Directors based on committee recommendations. Both appointees bring extensive experience in corporate governance and financial management.

17Nov 25

Panacea Biotec Reports Widened Q2 Net Loss and Revenue Decline

Panacea Biotec's Q2 results show a significant increase in net loss to ₹139.00 million from ₹48.00 million year-over-year. Revenue declined by 4.76% to ₹1.40 billion. EBITDA deteriorated from a positive ₹70.00 million to a loss of ₹178.00 million, indicating operational challenges. The company faces financial pressures with widening losses and declining revenue.

14Nov 25

Panacea Biotec Reports Widened Losses Despite Revenue Growth in Q2 FY2026

Panacea Biotec's Q2 FY2026 results show increased losses of ₹1,563.00 lakh, up from ₹668.00 lakh in Q2 FY2025. Total income rose to ₹9,442.00 lakh from ₹8,005.00 lakh. Revenue from operations increased to ₹9,081.00 lakh. The company recognized exceptional income of ₹1,402.00 lakh. Despite losses, management remains optimistic, citing surplus funds, strengthened working capital, new facilities for vaccine production, and scaling up of nutrition and pharmaceutical formulations business.

11Nov 25

Panacea Biotec Secures $4.75 Million Vaccine Supply Contract for 2026-2027

Panacea Biotec has secured a $4.75 million (~₹41 Crore) order for its Easyfive-TT vaccine from the Pan American Health Organization (PAHO). The contract, part of a Long-Term Agreement valid until December 31, 2027, covers supply for calendar years 2026 and 2027. Easyfive-TT is a pentavalent vaccine protecting against five diseases. This order strengthens Panacea Biotec's position in the international vaccine market, particularly in the Americas.

06Nov 25

Panacea Biotec Counters $7 Million Arbitration Claim in COVID-19 Technology Dispute

Panacea Biotec has filed its defense and counterclaims at the London Court of International Arbitration against Russia's Human Vaccine LLC. The dispute stems from a $7 million claim related to a COVID-19 vaccine Technology Transfer Agreement. Panacea Biotec denies liability, asserting that Human Vaccine's technology had deficiencies and that Panacea successfully manufactured the vaccine despite challenges. The company is seeking compensation for lost profits and expenses incurred. Panacea Biotec believes it will not be liable to repay the claimed amount based on its assessment and legal advice.

09Oct 25

Panacea Biotec Secures ₹127.20 Crore Order for Bivalent Oral Polio Vaccine and UNICEF Agreement

Panacea Biotec has received a ₹127.20 crore order from the Central Medical Services Society for supplying bivalent oral polio vaccine. The order will be delivered over 90 to 480 days. Additionally, UNICEF has awarded the company a long-term agreement worth $35.65 million for polio vaccines from 2026 to 2030.

03Oct 25

Panacea Biotec Secures ₹315 Crore Order from UNICEF for Polio Vaccine Supply

Panacea Biotec has received a ₹315 crore (US$ 35.65 million) order from UNICEF for bivalent oral polio vaccine (bOPV). The contract, spanning from April 1, 2026, to March 31, 2030, covers supply for Q2 CY2026 and CY2027. The vaccine will be supplied in 10 and 20 vial presentations for UNICEF's global polio eradication efforts. UNICEF will publish award details on its website for transparency. This order signifies a major business opportunity for Panacea Biotec in the global vaccine market.

24Sept 25

Panacea Biotec Launches Toxin-Free Baby Care Line and Infant Milk Substitute in India

Panacea Biotec's subsidiary, Panacea Biotec Pharma Limited, has introduced two new product lines in the Indian baby care market. 'NikoMom' is a 100% toxin-free baby care line featuring products like Baby Massage Oil, Baby Head to Toe Wash, Baby Daily Lotion, and Diaper Rash Cream. Each product uses advanced technologies for specific baby care needs. 'Staart Prime' is an infant milk substitute range for different stages of infant development. Both product lines will be available through various online and offline retail channels across India.

14Aug 25

Panacea Biotec Swings to Profit in Q1, Revenue Surges 44%

Panacea Biotec reported a consolidated net profit of ₹41 crore in Q1, compared to a loss of ₹158 crore last year. Revenue increased 44% to ₹1,667 crore. The company recorded an exceptional item of ₹113 crore, including ₹85.80 crore from a settlement with Apotex Inc. and ₹27.40 crore from brand sales. The vaccines segment reported revenue of ₹1,122.50 crore with a loss, while formulations generated ₹544.50 crore with a profit. The company is focusing on expanding vaccine manufacturing capacities and scaling up its nutrition and pharmaceutical formulations business.

29Jul 25

Panacea Biotec Secures Exchange Approval for Reclassification of Three Jain Family Members

Panacea Biotec Limited has received approval from BSE and NSE to reclassify three Jain family members from 'Promoters and Promoters' Group' to 'Public' category. The reclassification, approved on July 29, 2025, applies to Mrs. Sunanda Jain, Mr. Sumit Jain, and Ms. Radhika Jain. This change does not affect the company's shareholding structure, as the reclassified members hold no shares. Promoter holding remains at 72.48% and public holding at 27.52%. The reclassification complies with SEBI regulations.

11Jul 25

Panacea Biotec Faces Fresh GST Demand of 70.3 Million Rupees

Panacea Biotec has received a new GST demand of ₹70.3 million from the Assistant Commissioner of State Tax in Mumbai. This demand is related to a previous tax matter involving the transfer of leasehold rights in Navi Mumbai. The total amount includes ₹38.8 million in principal GST, ₹25.1 million in interest, and ₹6.5 million in penalties. Panacea Biotec believes the demand is not maintainable and is considering filing an appeal. The company does not expect this to significantly impact its financial or operational activities.

26Jun 25

Panacea Biotec May Face Challenges as US Halts Support for Global Vaccine Alliance Gavi

The US Health Secretary has announced a halt to support for the Global Vaccine Alliance (Gavi), which could have significant implications for vaccine manufacturers worldwide, including Panacea Biotec. This decision may affect vaccine distribution channels, ongoing research collaborations, market access in developing countries, and potentially the financial outlook for companies involved in Gavi-supported initiatives. The full impact on Panacea Biotec's operations remains uncertain, and stakeholders are advised to monitor for official statements from the company.

03Jun 25

Panacea Biotech's Emulsipan Adjuvant Gains Recognition in CEPI Library

Panacea Biotech announced the inclusion of its proprietary Emulsipan adjuvant in the Coalition for Epidemic Preparedness Innovations (CEPI) Adjuvant Library. This recognition highlights Emulsipan's potential in enhancing vaccine efficacy. The company also plans to commercialize its indigenously developed adjuvants, potentially opening new revenue streams. This development could enhance Panacea Biotech's global visibility, lead to new collaborations, and contribute to global health efforts in vaccine development.

30May 25

Panacea Biotec Reports Q4 Net Loss of ₹19 Crore, Revenue Dips

Panacea Biotec's Q4 financial results show a net loss of ₹19 crore, compared to a ₹14 crore loss in the same quarter last year. Revenue decreased by 4.41% year-on-year to ₹130 crore. This marks a shift from the previous quarter's profit of ₹45 crore, indicating volatility in the company's financial performance.

23Apr 25

Panacea Biotec Secures Additional $5.20 Million UNICEF Contract, Boosting Total Order Value to $20.15 Million

Panacea Biotec has expanded its contract with UNICEF for bivalent oral polio vaccine (bOPV) supply. The initial order of 115 million doses worth $14.95 million has been increased by an additional 40 million doses valued at $5.20 million. The total contract value now stands at $20.15 million (₹171.00 crore). The additional order will be delivered in Q3 CY2025, reinforcing the company's position in the global vaccine market and contributing to polio eradication efforts.